In this panel speakers will discuss new exciting projects and initiatives that are deepening our understanding of cannabis as medicine.
Dr. Jahan Marcu, Ph.D.
Dr. Stephen Corn, M.D.
Dr. Rick Doblin, Ph.D.
Dr. Dominic Corva, Ph.D.
Stephen B. Corn, MD is a board certified physician of Brigham and Women's Hospital and Children's Hospital, Boston, Massachusetts and Professor at Harvard Medical School. He specializes in anesthesiology, pain and perioperative medicine. He is also a prolific inventor and holds over 30 United States and international patents. His expertise in medical devices has resulted in his being named the first and only “Director of Clinical Innovation” for both Boston Children’s Hospital and Brigham & Women’s Hospital, Harvard Medical School.
Dr. Dominic Corva is Executive Director of The Center for the Study of Cannabis and Social Policy.
Rick Doblin is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment.
Jahan Marcu, Ph. D., is currently the Senior Scientist and Chief Auditor for Americans for Safe Access and the Patient Focused Certification (PFC) Program. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine (IACM). Dr. Marcu is the Director of Research and Development at Green Standard Diagnostics Inc. He received his Ph.D. for significant contributions to the study of the structure and function of the CB1 receptor, and the role of the endocannabinoid system in bone. Before earning his Ph.D., Dr. Marcu worked at the California Pacific Medical Center Research Institute studying the anti-cancer properties of compounds from the cannabis plant (Published in the Journal of Molecular Cancer Therapeutics) and on analytical Cannabis research projects in Holland. He is also an author of the American Herbal Pharmacopeia's Cannabis Monograph and one of the auditors for the Patient Focused Certification (PFC) program; an enforcement and oversight program that ensures that basic product safety protocols are followed at Cannabis operations. Dr. Marcu is a recipient of the Billy Martin research award from the International Cannabinoid Research Society.